Plasma adrenomedullin levels in migraine: A registry for migraine (REFORM) study.

IF 4.6 2区医学 Q1 CLINICAL NEUROLOGY

Cephalalgia Pub Date : 2025-08-01 Epub Date: 2025-08-10 DOI:10.1177/03331024251360234

Rogelio Dominguez-Moreno, William K Karlsson, Haidar M Al-Khazali, Rune H Christensen, Håkan Ashina, Messoud Ashina

{"title":"Plasma adrenomedullin levels in migraine: A registry for migraine (REFORM) study.","authors":"Rogelio Dominguez-Moreno, William K Karlsson, Haidar M Al-Khazali, Rune H Christensen, Håkan Ashina, Messoud Ashina","doi":"10.1177/03331024251360234","DOIUrl":null,"url":null,"abstract":"ObjectiveTo compare plasma adrenomedullin (AM) levels between adults with migraine and healthy controls (HCs), assessing subgroup differences and clinical associations.MethodsThis cross-sectional, observational single-center study was carried out from September 2020 to June 2022. Adults with migraine and HCs were enrolled and underwent blood sampling. Migraine subgroups included episodic migraine, chronic migraine, migraine without aura and migraine with aura. Plasma AM concentrations were quantified using a validated immunoluminometric assay by trained personnel who were blinded to group status.ResultsIn total, 667 participants with migraine and 147 HCs provided data eligible for analysis. Plasma AM concentrations did not differ significantly between the migraine and HC group (18.2 ± 9.1 pg/ml vs. 18.5 ± 8.4 pg/ml; p = 0.08). However, participants with episodic migraine exhibited lower AM levels than HCs (16.9 ± 7.7 pg/ml vs. 18.5 ± 8.4 pg/ml; p = 0.04). Multivariate regression models showed that plasma AM concentrations are positively associated with body mass index (4.2% increase in AM per kg/m2; 3.6 to 4.8%; p < 0.001) and monthly migraine days (0.6% increase in AM per MMD; 0.2 to 1.0%; p = 0.006).ConclusionsPlasma AM concentrations were comparable between participants with migraine and HCs; however, those with episodic migraine exhibited slightly lower levels. Future studies should investigate other candidate blood-based biomarkers for migraine.","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 8","pages":"3331024251360234"},"PeriodicalIF":4.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cephalalgia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03331024251360234","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

ObjectiveTo compare plasma adrenomedullin (AM) levels between adults with migraine and healthy controls (HCs), assessing subgroup differences and clinical associations.MethodsThis cross-sectional, observational single-center study was carried out from September 2020 to June 2022. Adults with migraine and HCs were enrolled and underwent blood sampling. Migraine subgroups included episodic migraine, chronic migraine, migraine without aura and migraine with aura. Plasma AM concentrations were quantified using a validated immunoluminometric assay by trained personnel who were blinded to group status.ResultsIn total, 667 participants with migraine and 147 HCs provided data eligible for analysis. Plasma AM concentrations did not differ significantly between the migraine and HC group (18.2 ± 9.1 pg/ml vs. 18.5 ± 8.4 pg/ml; p = 0.08). However, participants with episodic migraine exhibited lower AM levels than HCs (16.9 ± 7.7 pg/ml vs. 18.5 ± 8.4 pg/ml; p = 0.04). Multivariate regression models showed that plasma AM concentrations are positively associated with body mass index (4.2% increase in AM per kg/m²; 3.6 to 4.8%; p < 0.001) and monthly migraine days (0.6% increase in AM per MMD; 0.2 to 1.0%; p = 0.006).ConclusionsPlasma AM concentrations were comparable between participants with migraine and HCs; however, those with episodic migraine exhibited slightly lower levels. Future studies should investigate other candidate blood-based biomarkers for migraine.

查看原文本刊更多论文

偏头痛患者血浆肾上腺髓质素水平：偏头痛登记（REFORM）研究。

目的比较成人偏头痛患者与健康对照组（hc）血浆肾上腺髓质素（AM）水平，评估亚组差异及其临床相关性。方法本研究于2020年9月至2022年6月进行横断面、观察性单中心研究。研究人员招募了患有偏头痛和hc的成年人，并进行了血液采样。偏头痛亚组包括发作性偏头痛、慢性偏头痛、无先兆偏头痛和有先兆偏头痛。血浆AM浓度由训练有素的人员使用经过验证的免疫荧光测定法定量测定，这些人员对组状态不知情。结果共有667名偏头痛患者和147名hc患者提供了符合分析条件的数据。血浆AM浓度在偏头痛组和HC组之间无显著差异(18.2±9.1 pg/ml vs. 18.5±8.4 pg/ml；p = 0.08)。然而，发作性偏头痛患者的AM水平低于hc患者(16.9±7.7 pg/ml vs. 18.5±8.4 pg/ml；p = 0.04)。多变量回归模型显示血浆AM浓度与体重指数呈正相关(每kg/m2 AM增加4.2%；3.6% - 4.8%；p = 0.006)。结论：偏头痛和hc患者的血浆AM浓度具有可比性；然而，那些患有发作性偏头痛的人表现出稍低的水平。未来的研究应该研究偏头痛的其他候选血液生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cephalalgia 医学-临床神经学

CiteScore

10.10

自引率

6.10%

发文量

108

审稿时长

4-8 weeks

期刊介绍： Cephalalgia contains original peer reviewed papers on all aspects of headache. The journal provides an international forum for original research papers, review articles and short communications. Published monthly on behalf of the International Headache Society, Cephalalgia''s rapid review averages 5 ½ weeks from author submission to first decision.